Litcius/Paper detail

EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function

Yusuke Isshiki, Xi Chen, Matt Teater, Ioannis Karagiannidis, Henna S. Nam, Winson Cai, Cem Meydan, Min Xia, Hao Shen, Johana Gutierrez, Vigneshwari Easwar Kumar, Sebastian E. Carrasco, Madhu M. Ouseph, Samuel Yamshon, Peter Martin, Ofir Griess, Efrat Shema, Patrizia Porazzi, Marco Ruella, Renier J. Brentjens, Giorgio Inghirami, Roberta Zappasodi, Amy Chadburn, Ari Melnick, Wendy Béguelin

2024Cancer Cell59 citationsDOIOpen Access PDF

Topics & Concepts

Chimeric antigen receptorLymphomaCancer researchTumor microenvironmentT cellImmunotherapyCD8EZH2Follicular lymphomaT-cell lymphomaAntigenBiologyImmunologyImmunogenicityImmune systemEpigeneticsGeneBiochemistryCAR-T cell therapy researchImmune Cell Function and InteractionLymphoma Diagnosis and Treatment
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function | Litcius